相关实验视频
Updated: Jun 10, 2025

13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
5.6K
了解西斯胺诱导毒性的进展:分子机制和保护策略
Elsayed A Elmorsy1, Sameh Saber2, Rabab S Hamad3
1Department of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia.
概括
西斯是一种有效的癌症药物,但它会引起脏和神经损伤等有毒副作用. 本综述探讨了西斯的毒性机制,风险因素以及减少危害的新方法,以改善癌症治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 西斯是许多癌症的重要化疗药物.
- 它的使用受到严重毒性的限制,包括毒性,耳毒性,神经毒性和骨髓抑制.
- 了解这些毒性对于优化癌症治疗至关重要.
研究的目的:
- 为了提供对西斯胺诱导毒性的全面审查.
- 为了阐明机制,确定风险因素,并探索治疗策略.
- 增强 cisplatin 在癌症治疗中的临床应用.
主要方法:
- 关于西斯普拉丁毒性的临床前和临床研究的文献综述.
- 分析包括氧化应激,炎症,DNA损伤和亡在内的机制.
- 确定与患者相关的风险因素和潜在的保护性干预措施.
主要成果:
- 西斯普拉丁的毒性是多因素的,涉及细胞损伤途径.
- 预先存在的疾病,如病和神经病变,增加了易感性.
- 新兴的战略旨在减轻这些不利影响.
结论:
- 西斯普拉丁的毒性是一个重大的临床挑战.
- 个性化风险评估和新的治疗方法是必不可少的.
- 尽量减少毒性可以改善癌症护理中的患者结果和生活质量.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
149
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
149
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Electron Transport Chain: Complex I and II
12.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.0K

